Dynamic changes in monocytes subsets in COVID-19 patients

Qin, Shuang; Jiang, Yujie; Wei, Xin; Liu, Xiaoyuan; Guan, Jingjing; Chen, Yingxiao; Lu, Hong; Qian, Jingjing; Wang, Zhongyong; Lin, Xiangyang

doi:10.1016/j.humimm.2020.12.010

Cited by 54 publications

(65 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This complex displays foreign peptides to the immune system to trigger the immune response. Severe cases of COVID-19 have low expression of HLA-DR in blood monocytes (62)(63)(64). In concordance, our results suggest that the immune system of moderate patients led to an efficient response to COVID-19 infection.…”

Section: Monocyte Heterogeneity In Covid-19 Patientssupporting

confidence: 84%

On Deep Landscape Exploration of COVID-19 Patients Cells and Severity Markers

et al. 2021

View full text Add to dashboard Cite

COVID-19 is a disease with a spectrum of clinical responses ranging from moderate to critical. To study and control its effects, a large number of researchers are focused on two substantial aims. On the one hand, the discovery of diverse biomarkers to classify and potentially anticipate the disease severity of patients. These biomarkers could serve as a medical criterion to prioritize attention to those patients with higher prone to severe responses. On the other hand, understanding how the immune system orchestrates its responses in this spectrum of disease severities is a fundamental issue required to design new and optimized therapeutic strategies. In this work, using single-cell RNAseq of bronchoalveolar lavage fluid of nine patients with COVID-19 and three healthy controls, we contribute to both aspects. First, we presented computational supervised machine-learning models with high accuracy in classifying the disease severity (moderate and severe) in patients with COVID-19 starting from single-cell data from bronchoalveolar lavage fluid. Second, we identified regulatory mechanisms from the heterogeneous cell populations in the lungs microenvironment that correlated with different clinical responses. Given the results, patients with moderate COVID-19 symptoms showed an activation/inactivation profile for their analyzed cells leading to a sequential and innocuous immune response. In comparison, severe patients might be promoting cytotoxic and pro-inflammatory responses in a systemic fashion involving epithelial and immune cells without the possibility to develop viral clearance and immune memory. Consequently, we present an in-depth landscape analysis of how transcriptional factors and pathways from these heterogeneous populations can regulate their expression to promote or restrain an effective immune response directly linked to the patients prognosis.

show abstract

Section: Monocyte Heterogeneity In Covid-19 Patientssupporting

confidence: 84%

On Deep Landscape Exploration of COVID-19 Patients Cells and Severity Markers

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In our cohort, the number of monocytes in patients with DAC was reduced in comparison with patients with non-DAC ( Figure 1E ). Currently, reports have identified phenotypical alteration on monocytes of patients with COVID-19 ( 27 ), with a reduction in the antigen-presenting potential and an increase in the pro-inflammatory markers ( 28 ). Nevertheless, the reduction in monocytes of patients with DAC may also indicate a deficient immune response to SARS-CoV-2, as monocytes have a fundamental role in the immune response to pathogenic microorganisms ( 29 ).…”

Section: Resultsmentioning

confidence: 99%

“…Importantly, patients with COVID-19 also present phenotypical alteration on monocytes, increased pro-inflammatory response, and reduced antigen presentation potential ( 27 , 28 ). Although the role of monocytes' on COVID-19 is still under investigation, alcohol consumption may exacerbate the dysregulated profile of monocyte on COVID-19.…”

Section: Discussionmentioning

confidence: 99%

Clinical Characteristics and Survival Analysis in Frequent Alcohol Consumers With COVID-19

et al. 2021

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection can generate a systemic disease named coronavirus disease–2019 (COVID-19). Currently, the COVID-19 pandemic has killed millions worldwide, presenting huge health and economic challenges worldwide. Several risk factors, such as age, co-infections, metabolic syndrome, and smoking have been associated with poor disease progression and outcomes. Alcohol drinking is a common social practice among adults, but frequent and/or excessive consumption can mitigate the anti-viral and anti-bacterial immune responses. Therefore, we investigated if patients with self-reported daily alcohol consumption (DAC) presented alteration in the immune response to SARS-CoV-2. We investigated 122 patients with COVID-19 (101 male and 46 females), in which 23 were patients with DAC (18 men and 5 women) and 99 were non-DAC patients (58 men and 41 women), without other infections, neoplasia, or immunodeficiencies. Although with no difference in age, patients with DAC presented an increase in severity-associated COVID-19 markers such as C-reactive protein (CRP), neutrophil count, and neutrophil-to-lymphocyte ratio. In addition, patients with DAC presented a reduction in the lymphocytes and monocytes counts. Importantly, the DAC group presented an increase in death rate in comparison with the non-DAC group. Our results demonstrated that, in our cohort, DAC enhanced COVID-19-associated inflammation, and increased the number of deaths due to COVID-19.

show abstract

“…Monocyte rearrangement is likely to reflect the elevated IL-10 levels observed in COVID-19 patients. IL-10, as an inhibitory cytokine, prevents T-cell generation and thus disrupts and reduces T-cell activation and proliferation, leading to dysfunction of cellular immune responses (35). Furthermore, along SARS-CoV-2 induced viral infection, signal transducer and activator of IL-10 secretion led to overexpression of PD-1 and PD-L1 in monocytes and DCs (36).…”

Section: Discussionmentioning

confidence: 99%

PD-L1 Dysregulation in COVID-19 Patients

et al. 2021

View full text Add to dashboard Cite

The COVID-19 pandemic has reached direct and indirect medical and social consequences with a subset of patients who rapidly worsen and die from severe-critical manifestations. As a result, there is still an urgent need to identify prognostic biomarkers and effective therapeutic approaches. Severe-critical manifestations of COVID-19 are caused by a dysregulated immune response. Immune checkpoint molecules such as Programmed death-1 (PD-1) and its ligand programmed death-ligand 1 (PD-L1) play an important role in regulating the host immune response and several lines of evidence underly the role of PD-1 modulation in COVID-19. Here, by analyzing blood sample collection from both hospitalized COVID-19 patients and healthy donors, as well as levels of PD-L1 RNA expression in a variety of model systems of SARS-CoV-2, including in vitro tissue cultures, ex-vivo infections of primary epithelial cells and biological samples obtained from tissue biopsies and blood sample collection of COVID-19 and healthy individuals, we demonstrate that serum levels of PD-L1 have a prognostic role in COVID-19 patients and that PD-L1 dysregulation is associated to COVID-19 pathogenesis. Specifically, PD-L1 upregulation is induced by SARS-CoV-2 in infected epithelial cells and is dysregulated in several types of immune cells of COVID-19 patients including monocytes, neutrophils, gamma delta T cells and CD4+ T cells. These results have clinical significance since highlighted the potential role of PD-1/PD-L1 axis in COVID-19, suggest a prognostic role of PD-L1 and provide a further rationale to implement novel clinical studies in COVID-19 patients with PD-1/PD-L1 inhibitors.

show abstract

Dynamic changes in monocytes subsets in COVID-19 patients

Cited by 54 publications

References 24 publications

On Deep Landscape Exploration of COVID-19 Patients Cells and Severity Markers

On Deep Landscape Exploration of COVID-19 Patients Cells and Severity Markers

Clinical Characteristics and Survival Analysis in Frequent Alcohol Consumers With COVID-19

PD-L1 Dysregulation in COVID-19 Patients

Contact Info

Product

Resources

About